SCIENTIFIC REPORTS

OPEN

Mitochondrial fat oxidation is essential for lipid-induced inflammation in skeletal muscle in mice

Received: 27 May 2016
Accepted: 02 November 2016
Published: 28 November 2016

Jaycob D. Warfel¹, Estrellita M. Bermudez¹, Tamra M. Mendoza¹, Sujoy Ghosh^{2,3}, Jingying Zhang⁴, Carrie M. Elks⁵, Randall Mynatt^{1,4} & Bolormaa Vandanmagsar¹

Inflammation, lipotoxicity and mitochondrial dysfunction have been implicated in the pathogenesis of obesity-induced insulin resistance and type 2 diabetes. However, how these factors are intertwined in the development of obesity/insulin resistance remains unclear. Here, we examine the role of mitochondrial fat oxidation on lipid-induced inflammation in skeletal muscle. We used skeletal muscle-specific *Cpt1b* knockout mouse model where the inhibition of mitochondrial fatty acid oxidation results in accumulation of lipid metabolites in muscle and elevated circulating free fatty acids. Gene expression of pro-inflammatory cytokines, chemokines, and cytokine- and members of TLR-signalling pathways were decreased in *Cpt1b*^{m-/-} muscle. Inflammatory signalling pathways were not activated when evaluated by multiplex and immunoblot analysis. In addition, the inflammatory response to fatty acids was reduced in primary muscle cells derived from *Cpt1b*^{m-/-} mice. Gene expression of *Cd11c*, the M1 macrophage marker, was decreased; while *Cd206*, the M2 macrophage marker, was increased in skeletal muscle of *Cpt1b*^{m-/-} mice. Finally, expression of pro-inflammatory markers was decreased in white adipose tissue of *Cpt1b*^{m-/-} mice. We show that the inflammatory response elicited by elevated intracellular lipids in skeletal muscle is repressed in *Cpt1b*^{m-/-} mice, strongly supporting the hypothesis that mitochondrial processing of fatty acids is essential for the lipid-induction of inflammation in muscle.

Insulin resistance is tightly associated with obesity and is an essential part of type 2 diabetes and characterized by decreased glucose uptake in insulin-responsive organs¹. In obesity, elevated level of free fatty acids in circulation is associated with insulin resistance^{2,3}. Also accumulation of intracellular lipids such as ceramides and diacylglycerol (DAG) are linked to impaired insulin signalling in skeletal muscle^{4–8}. In addition, mitochondrial dysfunction with reduced or incomplete mitochondrial fatty acid oxidation (FAO) is associated with diminished insulin signalling^{9–14}.

Obesity is also characterized by the development of chronic inflammation in multiple tissues that contributes to insulin resistance^{15,16}. Dietary factors like saturated fatty acids have been proposed as triggers of metabolic inflammation. The consequences include production of pro-inflammatory cytokines and the recruitment of pro-inflammatory macrophages and lymphocytes to metabolic tissues^{17–20}. Inflammatory cytokines activate several kinases such as IKK β and JNK which interfere with insulin signalling in myocytes, hepatocytes, and adipocytes^{15,21,22}. However, how lipotoxicity and inflammation are intertwined in the pathogenesis of insulin resistance in obesity continues to remain elusive.

¹Gene Nutrient Interactions Laboratory, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana, USA. ²Computational Biology Laboratory, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana, USA. ³Centre for Computational Biology and Program in Cardiovascular and Metabolic Disorders, Duke-NUS Graduate Medical School, Singapore, Singapore. ⁴Transgenic Core Facility, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana, USA. ⁵Matrix Biology Laboratory, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana, USA. Correspondence and requests for materials should be addressed to B.V. (email: Bolormaa.Vandanmagsar@pbrc.edu)

Figure 1. Inhibition of mitochondrial fat oxidation in skeletal muscle does not induce inflammatory response in *Cpt1b^{m-/-}* mice. (a) Serum levels of IL1β and TNFα; n = 6–8/group. (b) Relative gene expression of *Tnfα* and *IL6* in gastrocnemius muscle measured by qPCR; n = 8/group. (c) FA-induced inflammatory gene expression in mouse primary muscle cells; n = 3/group. Data are means ± SEM; **p* < 0.05 significance for *Cpt1b^{m-/-}* mice vs control *Cpt1b^{fl/fl}* mice.

Carnitine palmitoyltransferase-1 (CPT1) is an enzyme located on the outer mitochondrial membrane that transports long-chain fatty acids into mitochondria for β-oxidation, thus controlling the rate of mitochondrial fatty acid oxidation (FAO). We recently described knockout mouse model with skeletal muscle specific *Cpt1b* depletion (*Cpt1b^{m-/-}*) that represent a model of FAO impairment and lipid accumulation in skeletal muscle²³. The physiological characterization of *Cpt1b^{m-/-}* mice has revealed many factors associated with obesity and insulin resistance, such as elevated levels of circulating free fatty acids and intramyocellular lipid (IMCL)²³. Though *Cpt1b^{m-/-}* mice clearly demonstrate diminished mitochondrial fat oxidation capacity and elevated lipid levels, they do not develop insulin resistance and have attenuated adiposity relative to control mice²³.

We have shown that the mTORC-Akt signalling pathway contributes to the increased expression of FGF21 in skeletal muscle of *Cpt1b^{m-/-}* mice, resulting in enhanced glucose utilization and insulin sensitivity²⁴. However, extensive investigation as to the inflammatory status of *Cpt1b^{m-/-}* mice has not yet been reported. Since these mice maintain biological markers associated with obesity and insulin resistance without developing obesity and diabetic phenotype, the study of inflammation in *Cpt1b^{m-/-}* mice, one of the major mechanisms in the pathogenesis of obesity-associated metabolic diseases, provides an opportunity to enhance the understanding of the relationship between obesity-induced inflammation and insulin resistance.

In the present study, we address whether lipotoxicity and reduced mitochondrial FAO in skeletal muscle contribute to obesity-associated inflammation using *Cpt1b^{m-/-}* mice. We demonstrate that *Cpt1b^{m-/-}* mice fed moderate fat diet do not manifest inflammation at the systemic level. Moreover, pro-inflammatory markers, inflammatory sensing, signalling and response are reduced in skeletal muscle, which may contribute to the maintenance of insulin sensitivity of *Cpt1b^{m-/-}* mice.

Results

Inhibition of mitochondrial fat oxidation in skeletal muscle prevents a local inflammatory response in *Cpt1b^{m-/-}* mice. *Cpt1b^{m-/-}* mice have elevated plasma lipids, and accumulation of both intramyocellular lipid (IMCL) and lipotoxic species such as DAG and ceramides, but they have lower fasting insulin and glucose, improved glucose tolerance, and no impairment of insulin signalling in skeletal muscle²³. We examined whether lipid overload in *Cpt1b^{m-/-}* mice induced inflammation in skeletal muscle and at the systemic level. Interestingly, serum levels of interleukin 1, IL1β and tumor necrosis factor alpha, TNFα did not differ between chow diet (CHD)-fed *Cpt1b^{m-/-}* and CHD-fed control *Cpt1b^{fl/fl}* mice (Fig. 1a). More interestingly, gene expression of pro-inflammatory cytokine *Tnfα* and chemokine C-C motif ligand 24, *Ccl24* was decreased in skeletal muscle tissue of *Cpt1b^{m-/-}* mice compared to control mice without changes in expression of interleukin 6, *IL6* (Fig. 1b and Table 1). Global analysis of gene expression and Gene Set Enrichment Analysis (GSEA) in

Gene symbol	Gene name	Changes	Significance
Casp3	caspase 3	↓	0.003
Casp9	caspase 9	↓	0.015
Ccl24	chemokine (C-C motif) ligand 24	↓	<0.0001
Cd27	CD27 antigene	↓	0.005
Ltb4r1	Leukotriene B4 receptor 1	↓	0.023
Lyz2 (LyzM)	Lysozyme 2	↓	0.038
Tab1	TGF-beta activated kinase 1/ MAP3K7 binding protein 1	↓	0.029
Tbkbp1	TBK1 binding protein 1	↓	0.001
Tlr6	Toll like receptor 6	↓	0.019
Traf1	TNF receptor-associated factor 1	↓	0.017

Table 1. Changes in expression of genes related to cytokine and chemokine signalling and inflammatory phenotype in *Cpt1b^{m-/-}* muscle. Gene expression data are obtained from Serial analysis of gene expression (SAGE) and Gene set enrichment analysis (GSEA) expression datasets in gastrocnemius muscle from *Cpt1b^{fl/fl}* and *Cpt1b^{m-/-}* mice; $n = 8$ (for *Cpt1b^{fl/fl}* mice) or $n = 7$ (for *Cpt1b^{m-/-}* mice). $p < 0.05$ was considered significant.

gastrocnemius muscle revealed that expression of pro-inflammatory cytokines and chemokines which are typically increased in obese state^{22,25–28} such as chemokine (C-C motif) ligands 2, 6, 7, 9, 11 (*Ccl2* (*Mcp1*), *Ccl6*, *Ccl7* (*Mcp3*), *Ccl9*, *Ccl11*) and chemokine (C-X-C motif) ligands 1, 9, 12 (*Cxcl1*, *Cxcl9*, *Cxcl12*), and their receptors, *IL6ra*, *Ccr1*, *Ccr2*, *Ccr3*, and *Cxcr4* was not changed in muscle tissue of *Cpt1b^{m-/-}* mice compared to *Cpt1b^{fl/fl}* mice (Supplementary Table S1). Also the same was true for $IL1\beta$ receptors *IL1r1* and *IL1r2*, and $TNF\alpha$ receptors *Tnfr1* and *Tnfr2* (Supplementary Table S1).

In line with this, fatty acid (FA)-induced expression of *Tnf α* , *IL6*, and *Casp9* was significantly decreased in *Cpt1b^{m-/-}* primary myotubes compared to *Cpt1b^{fl/fl}* myotubes, indicating that the inflammatory response to fatty acids is reduced in muscle cells from CHD-fed *Cpt1b^{m-/-}* mice (Fig. 1c). Notably, expression of *Tnf α* and *Casp9* was also significantly decreased in skeletal muscle tissue of high fat-diet (HFD) and low fat-diet (LFD) fed *Cpt1b^{m-/-}* mice compared to HFD and LFD fed *Cpt1b^{fl/fl}* mice, respectively (Supplementary Fig. S1a,b). However, expression of *IL6* was significantly decreased only in gastrocnemius muscle of HFD fed *Cpt1b^{m-/-}* mice, whereas it was not different in muscle tissue of LFD fed *Cpt1b^{m-/-}* and *Cpt1b^{fl/fl}* mice (Supplementary Fig. S1a,b). Taken together, these data suggest that inflammatory status is improved in skeletal muscle in *Cpt1b^{m-/-}* mice despite the presence of excess lipids at the systemic and tissue levels.

TLR-signalling is downregulated in skeletal muscle from *Cpt1b^{m-/-}* mice. Toll-like receptors (TLRs) are involved in bridging the immune response to metabolic disturbances as a nutrient sensor and as a part of inflammatory signalling^{29–31}. Increased amounts of FA directly induce Toll-like receptors (TLRs)^{25,32}. LPS, a metabolic endotoxin is also increased in obese, insulin resistant mice, and exacerbates inflammation via the TLR4-signalling³³. Next, we examined whether excess circulating FA stimulate TLR-signalling in muscle from *Cpt1b^{m-/-}* mice. The expression of *Tlr4*, *Tlr6*, and *Cd14*, the receptor for LPS-binding protein was significantly decreased in skeletal muscle from CHD fed *Cpt1b^{m-/-}* mice compared to CHD fed control mice (Fig. 2a and Table 1). Interestingly, gene expression of FA-transport proteins, *Cd36* and *Fatp1* was increased in *Cpt1b^{m-/-}* muscle, suggesting that FA overload on TLRs and FA uptake in *Cpt1b^{m-/-}* muscle are increased even in CHD condition compared to control mice (Fig. 2b). More interestingly, expression of *Tlr4* and *Cd14* was also significantly lower in muscle tissue from *Cpt1b^{m-/-}* mice compared to *Cpt1b^{fl/fl}* mice without changes in expression of *Tlr6* when mice were challenged with HFD (Supplementary Fig. S1a). However, expression of *Tlr1* and *Tlr2* in muscle was not different between CHD fed *Cpt1b^{m-/-}* and *Cpt1b^{fl/fl}* mice (Fig. 2a). Also, expression of *Tlr4*, *Tlr6*, and *Cd14* was not changed in muscle of LFD fed *Cpt1b^{m-/-}* mice compared to LFD fed control mice (Supplementary Fig. S1b). Together, these results suggest that the activity of TLR-signalling pathway is decreased in skeletal muscle of *Cpt1b^{m-/-}* mice despite increased levels of FA in circulation and consequently an excessive load of FA in muscle.

Inflammatory signalling pathways are not activated in *Cpt1b* deficient muscle. Next we examined activation of inflammatory pathways in skeletal muscle of *Cpt1b^{m-/-}* mice using Multiplex Mapmate assays. The mTORC1 pathway (the mammalian target of rapamycin, mTOR and its downstream target, p70 ribosomal S6 kinase or p70S6K) is involved in nutrient sensing and inflammatory signalling³⁴. Notably, the activity of mTORC1 signalling was decreased in white quad and gastrocnemius muscle in *Cpt1b^{m-/-}* mice compared to control mice (Fig. 2c). In the obese state, increased levels of fatty acids and cytokines in circulation induce activation of inflammatory signalling pathways such as STAT3 (signal transducer and activator of transcription 3), p38 MAPK (p38 mitogen-activated protein kinases) and NF κ B (nuclear factor kappa-light-chain-enhancer of activated B cells) in metabolic tissue^{35,36}. However, the activity of the inflammatory signalling pathways was not different in gastrocnemius muscle of *Cpt1b^{m-/-}* mice compared to *Cpt1b^{fl/fl}* mice (Fig. 2d).

In addition to phosphorylation at Ser 727, STAT3 is activated through phosphorylation at Tyr 705 in response to various cytokines including IFNs (interferons), IL5 and IL6 (interleukins 5 and 6)^{37–39}. However, immunoblot

Figure 2. Inflammatory signaling pathways are not activated in muscle of *Cpt1b^{m-/m-}* mice. (a,b)

Relative gene expression of TLR-members and *Cd14* (a), and fatty acid transport proteins *Cd36*, *Fatp1* (b) in gastrocnemius muscle of *Cpt1b^{fl/fl}* and *Cpt1b^{m-/m-}* mice measured by qPCR; $n = 8$ /group. (c,d) Activity of mTOR (c), and STAT3, p38 MAPK, and NFkB (d) pathways in gastrocnemius muscle of *Cpt1b^{fl/fl}* and *Cpt1b^{m-/m-}* mice evaluated by multiplex protein assay; $n = 5$ –11/group. (e) Activation of STAT3 pathway as examined by phosphorylation at Tyr 705 in gastrocnemius muscle of *Cpt1b^{fl/fl}* and *Cpt1b^{m-/m-}* mice evaluated by western blot analysis (left). Image J software was used for densitometry quantification of the immunoblots (right); $n = 5$ /group. Data are means $\pm$ SEM; * $p < 0.05$ and ** $p < 0.01$ and *** $p < 0.005$ significances for *Cpt1b^{m-/m-}* vs control *Cpt1b^{fl/fl}* mice.

analysis revealed that basal activation of STAT3 through Tyr 705 – phosphorylation in gastrocnemius muscle was similar between *Cpt1b^{fl/fl}* and *Cpt1b^{m-/m-}* mice (Fig. 2e).

In line with this, global gene expression analysis and GSEA analyses revealed that expression of intracellular signal transducers involved in TNF-mediated activation of NFkB, MAPK and JNK (c-Jun N-terminal kinases) pathways such as *Cd27* and *Traf1* (TNF receptor associated factor 1), and other members of TNFR-signalling pathways such as *Casp3* and *Casp9* were significantly decreased in skeletal muscle of *Cpt1b^{m-/m-}* mice compared to *Cpt1b^{fl/fl}* mice (Table 1). *Tab1* (TGF-beta activated kinase 1/MAP3K7 binding protein 1), *Tbkbp1* (TBK1 binding protein 1), *Tradd* (TNF receptor type 1-associated DEATH domain protein) and *Traf2* (TNF receptor associated factor 2) are members of TNF α /NFkB signal transduction network⁴⁰. Expression of *Tab1* and *Tbkbp1* was significantly reduced in *Cpt1b^{m-/m-}* muscle, whereas expression of *Tradd* and *Traf2* in skeletal muscle was not different between *Cpt1b^{m-/m-}* and *Cpt1b^{fl/fl}* mice (Table 1 and Supplementary Table S1).

Leukotriene B4 (LTB4) enhances macrophage chemotaxis and stimulates inflammatory pathways, and is increased in liver, muscle, and adipose tissue in HFD-fed obese mice, and directly promotes insulin resistance⁴¹. Inhibition of the LTB4 receptor, *Ltb4r1* leads to an anti-inflammatory phenotype and insulin sensitizing effects⁴¹. Interestingly, expression of *Ltb4r1* was significantly decreased in gastrocnemius muscle from *Cpt1b^{m-/m-}* mice compared to control mice (Table 1). However, expression of *IL1rap*, which is involved in IL1-signaling, and *IL6st*, an IL6 – signal transducer was not different in muscle tissue between *Cpt1b^{m-/m-}* and *Cpt1b^{fl/fl}* mice (Supplementary Table S1).

In addition to the evaluation of these selected genes, analysis of inflammation-associated pathways based on GSEA results obtained in gastrocnemius muscle from *Cpt1b^{m-/m-}* and control *Cpt1b^{fl/fl}* mice revealed that cytokine-cytokine receptor interaction pathways were significantly downregulated in muscle of *Cpt1b^{m-/m-}* mice (Fig. 3 and Supplementary Figs S2 and S3). Though the GSEA results and enrichment plot suggested that the natural killer (NK) cell-mediated cytotoxicity pathway is downregulated in muscle of *Cpt1b^{m-/m-}* mice,

Cytokine - cytokine receptor interaction

Figure 3. Cytokine-Cytokine receptor interaction pathway related gene expression pattern determined by Ingenuity Pathway Analysis (IPA) and Gene Set Enrichment Analysis (GSEA) in gastrocnemius muscle from *Cpt1b^{fl/fl}* (wt) and *Cpt1b^{fl/fl}* (ko) mice, n = 7–8/group.

the pathway adjusted p-value was at the borderline of significance (Fig. 4 and Supplementary Figs S4 and S5). Also, the chemokine signalling pathway was not different between *Cpt1b^{fl/fl}* and *Cpt1b^{fl/fl}* mice (Fig. 5 and Supplementary Fig. S6).

Taken together, these data indicate that cytokine-induced inflammatory signalling pathways are not activated in skeletal muscle of *Cpt1b^{fl/fl}* mice. Consistent with the reduction in expression of components which are involved in TNF α -mediated intracellular signal transduction, TNF α expression is decreased in *Cpt1b^{fl/fl}* muscle. However, expression of members involved in IL1 and IL6 signaling pathways is unaffected in *Cpt1b^{fl/fl}* muscle and, as a result, expression of IL1 β and IL6 is not changed in *Cpt1b^{fl/fl}* muscle.

***Cpt1b* ablation shifts immune cell function toward anti-inflammatory in skeletal muscle.** Another major characteristic of chronic inflammation in obesity is increased infiltration of pro-inflammatory immune cells in metabolic tissue when no source of infection or trauma is present⁴². To gain insight into whether

Natural killer cell-mediated cytotoxicity

Figure 4. Natural killer cell-mediated cytotoxicity related gene expression pattern determined by Ingenuity Pathway Analysis (IPA) and Gene Set Enrichment Analysis (GSEA) in gastrocnemius muscle from *Cpt1b^{fl/fl}* (wt) and *Cpt1b^{m-/-}* (ko) mice, n = 7–8/group.

immune cells in skeletal muscle of *Cpt1b^{m-/-}* mice contribute to reduction in inflammation in *Cpt1b* deficient muscle tissue, we evaluated immune cell populations by gene expression of cell markers in muscle. CD11c⁺ cells are classical pro-inflammatory M1 macrophages that are activated by FA^{43,44}, whereas CD206⁺ cells are known as anti-inflammatory oriented M2 macrophages^{43,45,46}. Notably, expression of *Cd11c* was significantly decreased (Fig. 6a), while expression of *Cd206* was significantly increased in skeletal muscle of *Cpt1b^{m-/-}* mice compared to *Cpt1b^{fl/fl}* mice when mice were fed CHD (Fig. 6b). In addition, expression of *Lyz2* (*LyzM*), a marker of mature myeloid cells such as monocytes, macrophages and neutrophils⁴⁷ was significantly decreased in *Cpt1b^{m-/-}* muscle (Table 1). However, expression of other pro-inflammatory macrophage markers *F4/80* and *Cd11b*, and T cell

Chemokine signaling

Figure 5. Chemokine signaling related gene expression pattern determined by Ingenuity Pathway Analysis (IPA) and Gene Set Enrichment Analysis (GSEA) in gastrocnemius muscle from *Cpt1b^{fl/fl}* (wt) and *Cpt1b^{m-/-}* (ko) mice, n = 7–8/group.

markers *Cd4* and *Cd8a*, and B cell marker *Cd19* was unchanged in *Cpt1b^{m-/-}* muscle compared to control *Cpt1b^{fl/fl}* muscle (Fig. 6).

In HFD fed mice, expression of pro-inflammatory macrophage markers, *F4/80* and *Cd11c* was significantly decreased in *Cpt1b^{m-/-}* muscle compared to control *Cpt1b^{fl/fl}* muscle, without change in expression of *Cd206* (Supplementary Fig. S1a). However, in LFD fed mice, none of the immune cell markers *F4/80*, *Cd11c*, and *Cd206* were changed in *Cpt1b^{m-/-}* muscle tissue compared to control mice (Supplementary Fig. S1b). Taken together, in contrast to obese mice, infiltration of immune cells is not enhanced in *Cpt1b^{m-/-}* muscle despite excess amounts of metabolic stimuli such as FA. Instead, a shift from M1 to M2 macrophages could favour reduced inflammation in *Cpt1b* deficient muscle.

Figure 6. Immune cell markers are not elevated in skeletal muscle of *Cpt1b^{m-/m-}* mice. (a,b) Relative gene expression of *F4/80*, *Cd11b*, *Cd11c* (a), and *Cd206*, *Cd4*, *Cd8a*, *Cd19* (b) in gastrocnemius muscle of *Cpt1b^{fl/fl}* and *Cpt1b^{m-/m-}* mice measured by qPCR; n = 8/group. Data are means ± SEM; **p* < 0.05 and ***p* < 0.01 and ****p* < 0.005 significances for *Cpt1b^{m-/m-}* vs control *Cpt1b^{fl/fl}* mice.

Changes in pro-inflammatory gene expression is not associated with fiber type in skeletal muscle of *Cpt1b^{m-/m-}* mice. Skeletal muscle consists of complex mixture of fibers, and different isoforms of myosin heavy chain (Myh) determine type 1 or 2 fibers^{48,49}. It has been demonstrated that resting healthy human muscles express cytokines in a fiber type specific manner⁵⁰. Pro-inflammatory cytokines TNFα and IL18 were exclusively expressed by type 2 fibers, whereas expression of IL6 was largely observed in type 1 fibers. We examined whether *Cpt1b*-deficiency affects fiber type composition and therefore plays a role in expression of inflammatory markers in muscle. We determined the distribution of the four major fiber types: 1, 2a, 2x, and 2b in skeletal muscle using expression of genes *Myh7* (MHC I), *Myh2* (MHC IIa), *Myh1* (MHC IIx), and *Myh4* (MHC IIb), respectively (Supplementary Fig. S7). Expression of *Myh7* was significantly increased and *Myh4* was significantly decreased in gastrocnemius muscle of *Cpt1b^{m-/m-}* mice compared to *Cpt1b^{fl/fl}* mice without changes in *Myh2* and *Myh1* expression, suggesting a possible fiber-type switch from type 2b to type 1 in *Cpt1b* deficient muscle.

Interestingly, a statistical correlation analysis revealed that expression of *Tnfα* was positively and significantly associated with expression of type 2a, 2x and 2b fiber genes in skeletal muscle of control *Cpt1b^{fl/fl}* mice (Supplementary Fig. S8). Notably, *Tnfα* expression was not associated with expression of any fiber-type genes in gastrocnemius muscle of *Cpt1b^{m-/m-}* mice. However, expression of *IL6* was not associated with expression of any fiber-type specific genes in either, control *Cpt1b^{fl/fl}* or *Cpt1b^{m-/m-}* mice (Supplementary Fig. S9). In addition to pro-inflammatory cytokines, correlation analysis revealed no association between expression of *Tlr4* and immune cell markers *F4/80*, *Cd11c* and *Cd206* with fiber-type specific genes in muscle of control *Cpt1b^{fl/fl}* mice and *Cpt1b* deficient mice (data not shown).

Taken together, *Cpt1b^{m-/m-}* muscle has more type 1 fibers and less type 2b fibers, however, it appears that fiber type distribution or fiber-switching does not affect expression of inflammatory markers or immune cell infiltration in skeletal muscle of *Cpt1b^{m-/m-}* mice.

Inflammatory status is improved in adipose tissue of *Cpt1b^{m-/m-}* mice. Adipose tissue is considered to be a main source of inflammation in obesity with increased production of pro-inflammatory cytokines and chemokines and infiltration of pro-inflammatory immune cells^{19,42,43,51,52}. We detected significantly decreased expression of cytokines *IL1β*, *IL6* and *Tnfα*, and chemokines *Ccl2*, *Cxcl9*, *Cxcl1*, *Cxcl5* and *Cxcl10* in epididymal white adipose tissue (eWAT) of *Cpt1b^{m-/m-}* mice compared to control *Cpt1b^{fl/fl}* mice, whereas expression of *Ccl9* was not different in these mice (Fig. 7a,b).

The expression of macrophage markers *F4/80*, *Cd11b*, and *Cd206*, T cell markers *Cd4* and *Cd8a*, and B lymphocyte marker *Cd19* was not different in adipose tissue of *Cpt1b^{m-/m-}* mice compared to *Cpt1b^{fl/fl}* mice (Fig. 7c,d). Notably, as a result of reduced production of chemokines including *Ccl2* and *Cxcl10*, which recruit monocytes to the site of inflammation, adipose tissue expression of M1 macrophage marker *Cd11c* was decreased in eWAT from *Cpt1b^{m-/m-}* mice compared to control *Cpt1b^{fl/fl}* mice (Fig. 7c). Taken together, decrease in expression of inflammatory markers such as pro-inflammatory cytokines and chemokines and infiltration of pro-inflammatory macrophages in adipose tissue of *Cpt1b^{m-/m-}* mice indicates that inflammatory status is improved in adipose tissue despite the elevated levels of lipids in circulation.

Discussion

Obesity-induced chronic inflammation is triggered by metabolic signals such as excess nutrients, and involves inflammatory responses originated within metabolic cells such as adipocytes, hepatocytes or myocytes, resulting in damage to metabolic homeostasis with insulin resistance^{16–18,36,42,53–55}. In agreement with these studies, we have previously found activated NFκB pathway and increased expression of pro-inflammatory genes in insulin resistant myotubes derived from diabetic-obese subjects, but not in insulin sensitive myotubes derived from non-diabetic-lean subjects⁵⁶. Thus, our data suggest that excess fat is sufficient to activate inflammatory signalling pathways in skeletal muscle resulting in elevated chemoattractant chemokines that in turn increase infiltration of pro-inflammatory immune cells in muscle.

Figure 7. Inflammatory status is improved in adipose tissue of *Cpt1b*^{m-/m-} mice. (a,b) Relative gene expression of *IL1β*, *IL6*, *Tnfα* (a) and chemokines (b) in epididymal white adipose tissue (eWAT) of *Cpt1b*^{fl/fl} and *Cpt1b*^{m-/m-} mice measured by qPCR; n = 8/group. Data are means ± SEM; *p < 0.05 and **p < 0.01 and ***p < 0.005 significances for *Cpt1b*^{m-/m-} vs control *Cpt1b*^{fl/fl} mice.

Cpt1b^{m-/m-} mice recapitulate a model of increased ectopic fat accumulation both in serum and in skeletal muscle. We have previously shown that when *Cpt1b* is knocked out in skeletal muscle, mice have diminished mitochondrial oxidative capacity of dietary fat²³. Surprisingly, this decrease in muscle mitochondrial function results in a lean, insulin sensitive phenotype characterized by decreased serum insulin and body weight due to reduced fat mass. *Cpt1b*^{m-/m-} mice on a CHD (25% calorie from fat) display behavioural differences from controls, including decreased food intake and decreased activity²³.

Despite a decrease in dietary intake, *Cpt1b*^{m-/m-} mice still maintain higher levels than controls of systemic and tissue lipids, which have classically been shown to be triggers of inflammatory response^{25,32}. Given that *Cpt1b*^{m-/m-} mice have these metabolic stressors even on CHD (25% calorie from fat), lipid-induced inflammation would be expected in this model. However, we demonstrate here that *Cpt1b*^{m-/m-} mice do not manifest inflammation in skeletal muscle or at the systemic level and do not possess a strong inflammatory response to the presence of elevated fatty acids. Sensing and signalling mechanisms which stand at the intersection of metabolic and inflammatory pathways such as TLRs, mTOR, JNK, MAPK, and NFκB that are activated in obesity-associated inflammation^{57–59}, were not induced in *Cpt1b*^{m-/m-} muscle. Moreover, the inflammatory response to excess lipids is decreased in *Cpt1b*-deficient muscle cells possibly leading to favourable changes in chemokine production that in turn results in a switch to anti-inflammatory function of immune cells in skeletal muscle of *Cpt1b*^{m-/m-} mice. Also, the fact that inflammatory response and recruitment of inflammatory immune cells in skeletal muscle of *Cpt1b*^{m-/m-} mice remained significantly lower compared to *Cpt1b*^{fl/fl} mice even when mice were fed HFD for a prolonged time suggest that the depletion of *Cpt1b* itself promotes a reduction of inflammatory markers independent of the diet. Furthermore, similar levels in expression of inflammatory markers such as TLR-signalling members and immune cell markers in muscle of LFD fed *Cpt1b*^{m-/m-} mice and LFD fed control mice suggest that depletion of CPT1b indeed keeps inflammatory status in muscle as low as at the LFD level (10% calorie from fat) even in mice fed CHD (25% calorie from fat) or HFD (45% calorie from fat).

Though the presence of elevated systemic and IMCL would tend to predict higher levels of inflammation, some of our previously reported results fall in line with the improved inflammatory status of *Cpt1b*^{m-/m-} mice. One key contributor to the activation of inflammatory signalling pathways and the inflammatory response in obese state is the metabolic stress of organelles such as mitochondria and endoplasmic reticulum (ER)⁴². However, previously we reported that mitochondrial and ER stress levels were not different in muscle between *Cpt1b*^{m-/m-} and control mice²⁴.

It has been shown that skeletal muscle produces cytokines dependent upon contraction^{60–63}. Though a decreased expression of inflammatory markers was not associated with fiber type switching in *Cpt1b*^{m-/m-} muscle, a reduced activity of *Cpt1b*^{m-/m-} mice could contribute to a reduction of contraction-induced cytokine response.

The beneficial effects of *Cpt1b* deficiency in muscle on inflammation are observed beyond skeletal muscle. Adipose tissue inflammation largely contributes to obesity-induced pro-inflammatory state and insulin resistance^{19,22,25,43,52}. We found that inflammation in adipose tissue with increased pro-inflammatory cytokines and chemokines, and infiltrated immune cells in obesity is absent in *Cpt1b*^{m-/m-} mice. We have reported that inhibition of mitochondrial fat oxidation in muscle induces FGF21 specifically in skeletal muscle of *Cpt1b*^{m-/m-} mice²⁴. FGF21 is also secreted into circulation as a myokine in *Cpt1b*^{m-/m-} mice and promotes browning of inguinal white adipose tissue (iWAT), but not eWAT in *Cpt1b*^{m-/m-} mice²⁴. Recent reports have shown that FGF21

decreased expression of IL6 and TNF α in adipose tissue of obese rats and suppressed inflammation in mouse models with FA-induced or diabetic renal dysfunction^{64,65}. Thus muscle derived FGF21 in *Cpt1b*^{m-/-} mice could have anti-inflammatory action locally in the presence of intracellular toxic lipids, and on adipose or possibly other tissues by circulation contributing to the improvement in inflammatory status at the face of constantly elevated systemic lipids.

Emerging evidence suggests the existence of a close relationship between metabolic and inflammatory systems^{5,15,22,66,67}. Our data show a coordinated decrease in mitochondrial processing of fatty acids and expression of inflammatory marker genes in skeletal muscle of *Cpt1b*^{m-/-} mice. On the other hand, we previously reported that pathways that are involved in amino acid, citric acid (TCA cycle), pyruvate and fatty acid metabolism, oxidative phosphorylation, and peroxisome function are upregulated in *Cpt1b*^{m-/-} muscle²³. Skeletal muscle uses the oxidation of lipids as a fuel during fasting periods and switches to the oxidation of carbohydrate during fed periods. Proper switching between different fuels is impaired in insulin resistant skeletal muscle^{68,69}. Notably, *Cpt1b*^{m-/-} mice successfully switch to usage of carbohydrates and amino acids, and use peroxisomal FAO to rescue decreased mitochondrial FAO in skeletal muscle²³. Accordingly, one explanation is that decreased inflammatory activity might be compensatory to increased metabolic function in *Cpt1b*^{m-/-} muscle. In line with this, we have reported increased expression of genes that are associated with mitochondrial branched-chain amino acid (BCAA) cycle such as *Bckdha* and *Bcat2*, and citric acid or tricarboxylic acid (TCA) cycle such as *Cs* and *Pdha1* with concomitant increase in leucine and pyruvate oxidation in *Cpt1b*^{m-/-} muscle²³. Previous studies have indicated that higher levels of TNF α are associated with decreased expression of BCAA/TCA cycle genes⁷⁰. The lower levels of TNF α expression reported in our study are therefore consistent with the observed enhanced expression of BCAA and TCA cycle genes in *Cpt1b*^{m-/-} mice.

In summary, our data suggest that elevated lipids within models of obesity and insulin resistance are not alone sufficient to induce chronic inflammation. Instead, metabolic status and homeostasis between metabolic systems and inflammatory mechanisms that prevents lipid-induced stress upon various cellular organelles such as the ER and mitochondria is important in the development of chronic inflammation in obesity. Specifically, our results presented here suggest that inhibition of CPT1 in skeletal muscle is protective against muscle and systemic inflammation despite the presence of excess lipid stressors possibly due to metabolic compensatory mechanisms developed to rescue impaired mitochondrial fat oxidation in skeletal muscle.

Methods

Animals. Animal studies were conducted at Pennington Biomedical Research Center's AALAC-approved facility using skeletal muscle specific *Cpt1b*^{m-/-} knockout mice where deletion of *Cpt1b* gene is driven by *Mlc1f* promoter²³. *Cpt1b*^{m-/-} and control *Cpt1b*^{fl/fl} mice have C57Bl6 background^{23,71}. All experiments were in compliance with the NIH Guide for the Care and Use of Laboratory Animals, and approved by the Institutional Animal Care and Use Committee at Pennington Biomedical Research Center. All mice utilized in the experiments were 5–6 month old males. Age matched *Cpt1b*^{m-/-} mice and control *Cpt1b*^{fl/fl} mice were fed a breeder's chow diet consisting of 25% calories from fat (Purina Rodent Chow no. 5015, Purina Mills, St. Louis, MO, USA). Also *Cpt1b*^{m-/-} and *Cpt1b*^{fl/fl} mice were fed a high fat-diet consisting of 45% calories from fat (D12451, Research Diets Inc, New Brunswick, NJ, USA) starting at 8 week of age for 16 weeks prior to the experiments, whereas mice from low fat-diet group were fed a chow diet consisting of 10% calories from fat (D12450, Research Diets Inc, New Brunswick, NJ, USA) starting at weaning age until they were utilized for experiments.

Mouse primary muscle cell culture. Cultures were established from mixed hindlimb muscle of 1 month old *Cpt1b*^{m-/-} and *Cpt1b*^{fl/fl} littermates²⁴. Collagenase digestion was used to isolate satellite cells (0.5% collagenase B, 1.2 U/ml Dispase II (Roche) in Ham's F-10 media (Thermo Scientific)), and enrichment in non-collagen coated flasks before initiation of culture and between passages used to reduce fibroblast content. Cells were maintained in collagen-coated flasks in Rat Skeletal Muscle Cell Growth Medium (Cell Applications, Inc, San Diego, CA, USA) and myoblasts at passage 3 were used for experiments. Briefly, the myoblasts at passage 2 were subcultured onto 24 well plates and grown to 80–90% confluence. Cells were then differentiated into fused multinucleated myotubes in Ham's F-10 media with 2% horse serum for 5–7 days. Myotubes were treated with either essentially fatty-acid free BSA or BSA-conjugated palmitate:oleate (1:1 ratio, total 0.5 mM) plus 2.5 mM carnitine. Treatments were performed in serum-free MEM alpha media with nucleosides (Gibco, Waltham, MA, USA) for 24 h and cells were harvested for gene expression analysis. At least three independent cultures were performed for each gene expression analysis by qRT-PCR and multiple wells (at least three replicates) were used per treatment.

Gene expression analysis. Total RNA from mouse tissue was isolated using RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and total RNA from mouse primary myotubes was isolated using RNeasy Micro Kit (Qiagen, Valencia, CA, USA). All samples were DNase digested to remove potential genomic DNA contamination. cDNA was synthesized with the iScript cDNA synthesis kit and used for qRT-PCR with the SYBR Green system (Bio-Rad, Hercules, CA, USA). qRT-PCR was conducted using $\Delta\Delta C_T$ assays. Mouse cyclophilin B was used for normalization of gene expression. Primer details are provided in Supplementary Table 2.

Serial Analysis of Gene Expression (SAGE). 1–2 μ g of total RNA extracted from mouse gastrocnemius muscle was used to perform the SAGE analysis as previously described⁷². Briefly, gene expression profiling was performed by expression tag sequencing (SAGE) on an AB SOLiD 5500XL next-generation sequencing instrument using reagent kits from the manufacturer (Applied Biosystems, Foster City, CA). Sequence reads were aligned to mouse RefSeq transcripts (version mm9) as the reference, utilizing the program SOLiDSAGE (Applied Biosystems). Only uniquely mapped sequence reads were counted to generate the expression count level for each respective RefSeq gene.

Global gene expression analysis and Gene Set Enrichment Analysis. Pathway enrichment was conducted via the gene set enrichment analysis procedure (GSEA) based on ranks⁷³. GSEA was performed by first weighting (ranking) the muscle gene expression data for the wild-type and Cpt1b^{-/-} groups via a signal-to-noise ratio (SNR) metric, and then employing a weighted Kolmogorov-Smirnov test to determine if the gene SNRs deviate significantly from a uniform distribution in a priori defined gene-sets (pathways). In our studies, these gene-sets were obtained from the Kyoto Encyclopedia of Genes and Genomes or KEGG⁷⁴ via the Molecular Signatures Database repository (MSigDb, <http://software.broadinstitute.org/gsea/msigdb/>). Statistical significance of the observed enrichment was ascertained by permutation testing over size-matched gene-sets. Significant gene-sets were selected by control of the false discovery rate, FDR at 25%⁷⁵. The per-sample expression profiles of genes contributing to core enrichment of the significant pathways were visualized via row-normalized blue-red heatmaps with blue representing lower, and red representing higher gene expression levels.

Multiplex analysis. Serum collections in mice were performed by submandibular bleed using BD micro-tainer SST (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Analytes (beads) for IL-1 β and TNF α (Bio-Rad, Hercules, CA, USA) were prepared according to the manufacturer instructions and Bio-Plex Mouse Cytokine Assay kit (Bio-Rad, Hercules, CA, USA) was used for serum multiplex assay.

Harvested muscle tissues from mice were snap frozen in liquid nitrogen. Muscle tissue was then powdered in liquid nitrogen and used for protein lysate preparation in Cell Signaling Lysis Buffer (Millipore, Billerica, MA, USA). Total protein lysates from mouse tissue powder were prepared according to the manufacturer's instructions and used for Multiplex Mapmate signaling assays. The following mouse Mapmates were used for cytokine signalling assay: p-JNK (Thr183/Tyr185), p-p38 MAPK (Thr180/Tyr182), p-mTOR (Ser2448) (Millipore); and p-STAT3 (Ser727), pNF κ B p65 (Ser536), p-P70S6K (Thr421/Ser424) (Bio-Rad). Milliplex Map Cell signaling buffer and Detection kits (Millipore) were used in all multiplex signalling assays and Map mates were prepared and combined according to the manufacturer instructions. 10 μ g of mouse tissue protein lysate was used in each assay and assays were run in duplicate. Mean fluorescence intensity (MFI) of phospho-proteins was measured on a Luminex 200 Analyzer (Millipore) and analyzed using Milliplex Analyst Software (Millipore).

Western blot analysis. Gastrocnemius homogenates were prepared in a non-denaturing buffer (2% Triton X-100, 300 mM NaCl, 20 mM Tris (pH 7.4), 2 mM EDTA, 2 mM EGTA, and 1% NP-40) containing the following phosphatase and protease inhibitors: 1 mM PMSF, 10 uM leupeptin, 38 uM aprotinin, 1 mM phenanthroline, 1 uM pepstatin, 1 mM sodium fluoride, and 200 uM sodium vanadate. Total protein concentrations were measured using a bicinchoninic acid assay (ThermoFisher Scientific). Western blot analysis (200 μ g protein/well) was performed using standard procedures followed by Odyssey IF detection. The antibodies used were pSTAT3 (Tyr705) from BD Transduction Laboratories and STAT3 from Santa Cruz Biotechnology. Densitometric analysis was performed using ImageJ software (NIH).

Statistical Analyses. GraphPad Prism 5 software, Student's *t* test and Pearson's correlation coefficient *r* were used for statistical analysis. All data are presented as the mean $\pm$ SEM. *p* < 0.05 was considered statistically significant.

References

- Samuel, V. T. & Shulman, G. I. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. *J Clin Invest* **126**, 12–22 (2016).
- McGarry, J. D. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. *Diabetes* **51**, 7–18 (2002).
- Shulman, G. I. Cellular mechanisms of insulin resistance. *J Clin Invest* **106**, 171–176 (2000).
- Unger, R. H. Lipotoxic diseases. *Annu Rev Med* **53**, 319–336 (2002).
- Wellen, K. E. & Hotamisligil, G. S. Inflammation, stress, and diabetes. *J Clin Invest* **115**, 1111–1119 (2005).
- Chavez, J. A. *et al.* A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. *J Biol Chem* **278**, 10297–10303 (2003).
- Aguer, C. *et al.* Acylcarnitines: potential implications for skeletal muscle insulin resistance. *FASEB J* **29**, 336–345 (2015).
- Koves, T. R. *et al.* Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. *Cell Metab* **7**, 45–56 (2008).
- Kelley, D. E. & Simoneau, J. A. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. *J Clin Invest* **94**, 2349–2356 (1994).
- Gaster, M., Rustan, A. C., Aas, V. & Beck-Nielsen, H. Reduced lipid oxidation in skeletal muscle from type 2 diabetic subjects may be of genetic origin: evidence from cultured myotubes. *Diabetes* **53**, 542–548 (2004).
- Kim, J. Y., Hickner, R. C., Cortright, R. L., Dohm, G. L. & Houmard, J. A. Lipid oxidation is reduced in obese human skeletal muscle. *Am J Physiol Endocrinol Metab* **279**, E1039–E1044 (2000).
- Morino, K., Petersen, K. F. & Shulman, G. I. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. *Diabetes* **55** Suppl 2, S9–S15 (2006).
- Lowell, B. B. & Shulman, G. I. Mitochondrial dysfunction and type 2 diabetes. *Science* **307**, 384–387 (2005).
- Goodpaster, B. H. Mitochondrial deficiency is associated with insulin resistance. *Diabetes* **62**, 1032–1035 (2013).
- Lackey, D. E. & Olefsky, J. M. Regulation of metabolism by the innate immune system. *Nat Rev Endocrinol* **12**, 15–28 (2016).
- Zeyda, M. & Stulnig, T. M. Obesity, inflammation, and insulin resistance—a mini-review. *Gerontology* **55**, 379–386 (2009).
- Tanti, J. F., Ceppo, F., Jager, J. & Berthou, F. Implication of inflammatory signaling pathways in obesity-induced insulin resistance. *Front Endocrinol (Lausanne)* **3**, 181 (2012).
- Pillon, N. J., Bilan, P. J., Fink, L. N. & Klip, A. Cross-talk between skeletal muscle and immune cells: muscle-derived mediators and metabolic implications. *Am J Physiol Endocrinol Metab* **304**, E453–E465 (2013).
- Weisberg, S. P. *et al.* Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest* **112**, 1796–1808 (2003).
- Varma, V. *et al.* Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. *Am J Physiol Endocrinol Metab* **296**, E1300–E1310 (2009).
- Tanti, J. F. & Jager, J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. *Curr Opin Pharmacol* **9**, 753–762 (2009).

22. Lumeng, C. N. & Saltiel, A. R. Inflammatory links between obesity and metabolic disease. *J Clin Invest* **121**, 2111–2117 (2011).
23. Wicks, S. E. *et al.* Impaired mitochondrial fat oxidation induces adaptive remodeling of muscle metabolism. *Proc Natl Acad Sci USA* **112**, E3300–3309 (2015).
24. Vandanmagsar, B. *et al.* Impaired Mitochondrial Fat Oxidation Induces FGF21 in Muscle. *Cell Rep* **15**, 1686–1699 (2016).
25. Hotamisligil, G. S. & Erbay, E. Nutrient sensing and inflammation in metabolic diseases. *Nat Rev Immunol* **8**, 923–934 (2008).
26. Sell, H., Dietze-Schroeder, D., Kaiser, U. & Eckel, J. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. *Endocrinology* **147**, 2458–2467 (2006).
27. Nedachi, T., Hatakeyama, H., Kono, T., Sato, M. & Kanzaki, M. Characterization of contraction-inducible CXC chemokines and their roles in C2C12 myocytes. *Am J Physiol Endocrinol Metab* **297**, E866–878 (2009).
28. Arkan, M. C. *et al.* IKK-beta links inflammation to obesity-induced insulin resistance. *Nat Med* **11**, 191–198 (2005).
29. Odegaard, J. I. & Chawla, A. The immune system as a sensor of the metabolic state. *Immunity* **38**, 644–654 (2013).
30. Boyd, J. H. *et al.* Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-kappaB and calcineurin. *Infect Immun* **74**, 6829–6838 (2006).
31. Reyna, S. M. *et al.* Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. *Diabetes* **57**, 2595–2602 (2008).
32. Dasu, M. R., Ramirez, S. & Isseroff, R. R. Toll-like receptors and diabetes: a therapeutic perspective. *Clin Sci (Lond)* **122**, 203–214 (2012).
33. Kim, K. A., Gu, W., Lee, I. A., Joh, E. H. & Kim, D. H. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. *PLoS One* **7**, e47713 (2012).
34. Wullschlegel, S., Loewith, R. & Hall, M. N. TOR signaling in growth and metabolism. *Cell* **124**, 471–484 (2006).
35. Hotamisligil, G. S. Inflammation and metabolic disorders. *Nature* **444**, 860–867 (2006).
36. Kewalramani, G., Bilan, P. J. & Klip, A. Muscle insulin resistance: assault by lipids, cytokines and local macrophages. *Curr Opin Clin Nutr Metab Care* **13**, 382–390 (2010).
37. Heinrich, P. C. *et al.* Principles of interleukin (IL)-6-type cytokine signalling and its regulation. *Biochem J* **374**, 1–20 (2003).
38. Caldenhoven, E. *et al.* STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. *J Biol Chem* **271**, 13221–13227 (1996).
39. Ho, H. H. & Ivashkiv, L. B. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. *J Biol Chem* **281**, 14111–14118 (2006).
40. Bouwmeester, T. *et al.* A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. *Nat Cell Biol* **6**, 97–105 (2004).
41. Li, P. *et al.* LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. *Nat Med* **21**, 239–247 (2015).
42. Gregor, M. F. & Hotamisligil, G. S. Inflammatory mechanisms in obesity. *Annu Rev Immunol* **29**, 415–445 (2011).
43. Vandanmagsar, B. *et al.* The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. *Nat Med* **17**, 179–188 (2011).
44. Nguyen, M. T. *et al.* A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. *J Biol Chem* **282**, 35279–35292 (2007).
45. Gordon, S. & Taylor, P. R. Monocyte and macrophage heterogeneity. *Nat Rev Immunol* **5**, 953–964 (2005).
46. Fujisaka, S. *et al.* Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. *Diabetes* **58**, 2574–2582 (2009).
47. Faust, N., Varas, F., Kelly, L. M., Heck, S. & Graf, T. Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. *Blood* **96**, 719–726 (2000).
48. Weiss, A. & Leinwand, L. A. The mammalian myosin heavy chain gene family. *Annu Rev Cell Dev Biol* **12**, 417–439 (1996).
49. Smerdu, V., Karsch-Mizrachi, I., Campione, M., Leinwand, L. & Schiaffino, S. Type IIx myosin heavy chain transcripts are expressed in type IIb fibers of human skeletal muscle. *Am J Physiol* **267**, C1723–1728 (1994).
50. Plomgaard, P., Penkowa, M. & Pedersen, B. K. Fiber type specific expression of TNF-alpha, IL-6 and IL-18 in human skeletal muscles. *Exerc Immunol Rev* **11**, 53–63 (2005).
51. Xu, H. *et al.* Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* **112**, 1821–1830 (2003).
52. Yang, H. *et al.* Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. *J Immunol* **185**, 1836–1845 (2010).
53. Bilan, P. J. *et al.* Direct and macrophage-mediated actions of fatty acids causing insulin resistance in muscle cells. *Arch Physiol Biochem* **115**, 176–190 (2009).
54. Fink, L. N. *et al.* Pro-inflammatory macrophages increase in skeletal muscle of high fat-fed mice and correlate with metabolic risk markers in humans. *Obesity (Silver Spring)* **22**, 747–757 (2014).
55. Wu, Y. *et al.* Chronic inflammation exacerbates glucose metabolism disorders in C57BL/6J mice fed with high-fat diet. *J Endocrinol* **219**, 195–204 (2013).
56. Vandanmagsar, B. *et al.* Artemisia dracunculus L. extract ameliorates insulin sensitivity by attenuating inflammatory signalling in human skeletal muscle culture. *Diabetes Obes Metab* **16**, 728–738 (2014).
57. Radin, M. S., Sinha, S., Bhatt, B. A., Dedousis, N. & O'Doherty, R. M. Inhibition or deletion of the lipopolysaccharide receptor Toll-like receptor-4 confers partial protection against lipid-induced insulin resistance in rodent skeletal muscle. *Diabetologia* **51**, 336–346 (2008).
58. Senn, J. J. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. *J Biol Chem* **281**, 26865–26875 (2006).
59. Ivashkiv, L. B. Inflammatory signaling in macrophages: transitions from acute to tolerant and alternative activation states. *Eur J Immunol* **41**, 2477–2481 (2011).
60. Pedersen, B. K. & Febbraio, M. A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. *Nat Rev Endocrinol* **8**, 457–465 (2012).
61. Allen, J., Sun, Y. & Woods, J. A. Exercise and the Regulation of Inflammatory Responses. *Prog Mol Biol Transl Sci* **135**, 337–354 (2015).
62. Pedersen, B. K. *et al.* Exercise and cytokines with particular focus on muscle-derived IL-6. *Exerc Immunol Rev* **7**, 18–31 (2001).
63. Pedersen, B. K. Muscular interleukin-6 and its role as an energy sensor. *Med Sci Sports Exerc* **44**, 392–396 (2012).
64. Wang, W. F. *et al.* Recombinant murine fibroblast growth factor 21 ameliorates obesity-related inflammation in monosodium glutamate-induced obesity rats. *Endocrine* (2014).
65. Zhang, C. *et al.* Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation. *PLoS One* **8**, e82275 (2013).
66. Odegaard, J. I. & Chawla, A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. *Science* **339**, 172–177 (2013).
67. O'Neill, L. A. & Hardie, D. G. Metabolism of inflammation limited by AMPK and pseudo-starvation. *Nature* **493**, 346–355 (2013).
68. Galgani, J. E., Moro, C. & Ravussin, E. Metabolic flexibility and insulin resistance. *Am J Physiol Endocrinol Metab* **295**, E1009–1017 (2008).

69. Muoio, D. M. & Neufer, P. D. Lipid-induced mitochondrial stress and insulin action in muscle. *Cell Metab* **15**, 595–605 (2012).
70. Burrill, J. S. *et al.* Inflammation and ER stress regulate branched-chain amino acid uptake and metabolism in adipocytes. *Mol Endocrinol* **29**, 411–420 (2015).
71. Haynie, K. R., Vandanmagsar, B., Wicks, S. E., Zhang, J. & Mynatt, R. L. Inhibition of carnitine palmitoyltransferase1b induces cardiac hypertrophy and mortality in mice. *Diabetes Obes Metab* **16**, 757–760 (2014).
72. Salbaum, J. M. *et al.* Novel Mode of Defective Neural Tube Closure in the Non-Obese Diabetic (NOD) Mouse Strain. *Sci Rep* **5**, 16917 (2015).
73. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA* **102**, 15545–15550 (2005).
74. Ogata, H. *et al.* KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res* **27**, 29–34 (1999).
75. Reiner, A., Yekutieli, D. & Benjamini, Y. Identifying differentially expressed genes using false discovery rate controlling procedures. *Bioinformatics* **19**, 368–375 (2003).

Acknowledgements

We thank Dieyun Ding for technical assistance and Rob Noland for helpful advice. J.D.W. is supported by Fellowship T32DK6458413. C.M.E. is supported by KO1 DK106307 from the NIH. This work was supported by NIH grant R01DK089641 to R.L.M. This work used the PBRC facilities of the Transgenic, Comparative Biology, Genomics Core and Clinical Research Laboratory supported in part by COBRE (NIH 8P20GM103528) and the NORC (NIH 2P30-DK072476-11A1) center grants from the National Institutes of Health.

Author Contributions

Data collection and manuscript preparation: J.D.W., R.L.M. and B.V.; Data analysis: S.G.; Technical Assistance: E.M.B., T.M.M., J.Z. and C.M.E.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Warfel, J. D. *et al.* Mitochondrial fat oxidation is essential for lipid-induced inflammation in skeletal muscle in mice. *Sci. Rep.* **6**, 37941; doi: 10.1038/srep37941 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016